I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$68.00|
|52 Week High||US$32.64|
|52 Week Low||US$85.40|
|1 Month Change||0.43%|
|3 Month Change||-12.83%|
|1 Year Change||77.92%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||444.00%|
Recent News & Updates
|IMAB||US Biotechs||US Market|
Return vs Industry: IMAB exceeded the US Biotechs industry which returned 31% over the past year.
Return vs Market: IMAB exceeded the US Market which returned 37.5% over the past year.
Stable Share Price: IMAB is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: IMAB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 1a clinical trials with RBC-sparing differentiation; and Olamkicept, an IL-6 blocker that has completed Phase 2 clinical trials for the treatment of ulcerative colitis and autoimmune. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat glioblastoma multiforme patients with lymphopenia; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody that is in Phase 2 clinical trials for rheumatoid arthritis and CAR-T-related therapies; Uliledlimab, a CD73 antibody, which is in Phase I/2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers.
I-Mab Fundamentals Summary
|IMAB fundamental statistics|
Is IMAB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMAB income statement (TTM)|
|Cost of Revenue||CN¥0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.30|
|Net Profit Margin||-1.46%|
How did IMAB perform over the long term?See historical performance and comparison
Is I-Mab undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: IMAB ($68) is trading above our estimate of fair value ($29.21)
Significantly Below Fair Value: IMAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: IMAB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: IMAB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMAB is overvalued based on its PB Ratio (6.2x) compared to the US Biotechs industry average (3.3x).
How is I-Mab forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMAB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMAB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMAB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMAB's revenue (37.1% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: IMAB's revenue (37.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IMAB is forecast to be unprofitable in 3 years.
How has I-Mab performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMAB is currently unprofitable.
Growing Profit Margin: IMAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMAB is unprofitable, but has reduced losses over the past 5 years at a rate of 21.8% per year.
Accelerating Growth: Unable to compare IMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: IMAB has a negative Return on Equity (-0.42%), as it is currently unprofitable.
How is I-Mab's financial position?
Financial Position Analysis
Short Term Liabilities: IMAB's short term assets (CN¥5.2B) exceed its short term liabilities (CN¥550.6M).
Long Term Liabilities: IMAB's short term assets (CN¥5.2B) exceed its long term liabilities (CN¥137.7M).
Debt to Equity History and Analysis
Debt Level: IMAB is debt free.
Reducing Debt: IMAB had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable IMAB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: IMAB is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 4.4% per year.
What is I-Mab current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joan Shen (59 yo)
Dr. Joan Huaqiong Shen, M.D., Ph D., has been Chief Executive Officer of I-Mab since October 2019 and also has been its Director since July 2019. Dr. Shen served as Head of Discovery & Clinical Development...
Experienced Management: IMAB's management team is considered experienced (2.5 years average tenure).
Experienced Board: IMAB's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.
I-Mab's employee growth, exchange listings and data sources
- Name: I-Mab
- Ticker: IMAB
- Exchange: NasdaqGM
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.233b
- Shares outstanding: 76.96m
- Website: https://www.i-mabbiopharma.com
Number of Employees
- West Tower, OmniVision
- Suite 802
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 02:26|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.